These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 16178117)

  • 21. Using market-exclusivity incentives to promote pharmaceutical innovation.
    Kesselheim AS
    N Engl J Med; 2010 Nov; 363(19):1855-62. PubMed ID: 21047231
    [No Abstract]   [Full Text] [Related]  

  • 22. Drug costs threaten patent protection.
    Cimons M
    Nat Med; 2003 Jan; 9(1):9. PubMed ID: 12514706
    [No Abstract]   [Full Text] [Related]  

  • 23. Sales from licensed and acquired products to increase by 2013.
    Goodman M
    Nat Rev Drug Discov; 2009 Jun; 8(6):443. PubMed ID: 19483704
    [No Abstract]   [Full Text] [Related]  

  • 24. The people vs patents.
    New Sci; 2002 Jul; 175(2351):3. PubMed ID: 12625337
    [No Abstract]   [Full Text] [Related]  

  • 25. Patent reform in the US: what's at stake for pharmaceutical innovation?
    Yancey A; Stewart CN
    Expert Opin Ther Pat; 2010 May; 20(5):603-8. PubMed ID: 20402544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A day late and a few million dollars short.
    Goldenson D
    Nat Biotechnol; 2009 Jun; 27(6):538-41. PubMed ID: 19513055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity.
    Berger JM
    Conn J Int Law; 2002; 17(2):157-248. PubMed ID: 12688292
    [No Abstract]   [Full Text] [Related]  

  • 28. The WTO dispute settlement understanding: an unlikely weapon in the fight against AIDS.
    Curti AM
    Am J Law Med; 2001; 27(4):469-85. PubMed ID: 11837145
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost-effectiveness data on biologics needed.
    Sheridan C; Katsnelson A
    Nat Biotechnol; 2005 Mar; 23(3):272-3. PubMed ID: 15765069
    [No Abstract]   [Full Text] [Related]  

  • 30. Maintaining patents protecting biologics or small-molecule drugs.
    Marimuthu G; Kumari S; Kandasamy M; Raghunathan S; Saberwal G
    Nat Biotechnol; 2012 Jan; 30(1):50-3. PubMed ID: 22231094
    [No Abstract]   [Full Text] [Related]  

  • 31. Policy making on data exclusivity in the European Union: from industrial interests to legal realities.
    Adamini S; Maarse H; Versluis E; Light DW
    J Health Polit Policy Law; 2009 Dec; 34(6):979-1010. PubMed ID: 20018988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. It is not unethical, though it is often unwise, to override patents.
    Leventer H
    Am J Bioeth; 2002; 2(3):50-1. PubMed ID: 12230860
    [No Abstract]   [Full Text] [Related]  

  • 33. Replace pharmaceutical patents now.
    Grinols EL; Henderson JW
    Pharmacoeconomics; 2007; 25(5):355-63. PubMed ID: 17488135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patent term extension: an expensive and unnecessary giveaway.
    Gore A
    Health Aff (Millwood); 1982; 1(2):25-33. PubMed ID: 10621692
    [No Abstract]   [Full Text] [Related]  

  • 35. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
    't Hoen E
    Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
    [No Abstract]   [Full Text] [Related]  

  • 36. Mergers in Japan help firms retain own products.
    Fuyuno I
    Nat Rev Drug Discov; 2005 May; 4(5):358. PubMed ID: 15902766
    [No Abstract]   [Full Text] [Related]  

  • 37. Intellectual property rights, compulsory licensing and the TRIPS agreement: some ethical issues.
    Schuklenk U
    Monash Bioeth Rev; 2003 Apr; 22(2):63-8. PubMed ID: 15069958
    [No Abstract]   [Full Text] [Related]  

  • 38. Reach-through claims for drug target patents: Rx for pharmaceutical policy.
    Bohrer RA
    Nat Biotechnol; 2008 Jan; 26(1):55-6. PubMed ID: 18183015
    [No Abstract]   [Full Text] [Related]  

  • 39. Patent indicators: a window to pharmaceutical market success.
    Guo Y; Hu Y; Zheng M; Wang Y
    Expert Opin Ther Pat; 2013 Jul; 23(7):765-71. PubMed ID: 23611022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Data and market exclusivity for pharmaceuticals in the European Community.
    Kingham RF; Castle GH
    Food Drug Law J; 2000; 55(2):209-23. PubMed ID: 12269365
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.